Skip to content

Effect of Gudadyavaleha on Gut Microbiome and Clinical Profile in Tamak Swas w.s.r. Childhood Bronchial Asthma

Effect of Gudadyavaleha on Gut Microbiome and Clinical Profile in Tamak Swas w.s.r. Childhood Bronchial Asthma:An Open Label Interventional Trial - NILL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/063402
Enrollment
30
Registered
2024-03-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

None listed

Sponsors

National Institute of Ayurveda, Jaipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children of either sex in between age group of 10 to 16 years 2. Known case of asthma having recent history of asthmatic attacks. 3. Minimum 3 episodes of mild to moderate bronchial asthma per year persisting for 1 week. 4. Having clinical features of bronchial asthma Tamaka Shwasa and satisfying Subjective parameters grading for the disease.

Exclusion criteria

Exclusion criteria: 1. Abnormal body mass index BMI more than 28 or less than 18.5. 2. Unusual dietetic regimen. 3. Autoimmune diseases, inflammatory bowel disease, diarrhea 4 weeks before taking the stool sample. 4. Antibiotic, probiotic, or vitamin administration less than 1 month before fecal sampling, those who received immunosuppressive therapy and allergen-specific immunotherapy in the last 5 years. 5. Patient on oral or inhaled glucocorticoid treatment during 6 months prior to the sample collection date. 6. Having severe feature of bronchial asthma or Status asthmaticus. 7. Asthmatic child with comorbidities like Tuberculosis, Nasal Polyps, Pleural effusion, Emphysema, Bronchiectasis etc. 8. Patient or parents or attendant not willing to be a part of the clinical trial.

Design outcomes

Primary

MeasureTime frame
•Decrease in severity and frequency of Asthmatic Attacks •Change in gut microbiome profile •Change in Cytokine IL-4 levels, Serum IgE, PEFR, FEV1, TEC Timepoint: 8 weeks

Secondary

MeasureTime frame
•Reduce the risk of severe attacks and improving the quality of lifeTimepoint: 8 weeks

Countries

India

Contacts

Public ContactDr Ankita Mishra

National Institute of Ayurveda, Jaipur

drnishaojha@gmail.com9468650449

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026